End-stage Renal Disease (ESRD) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 End-stage renal disease (ESRD) is the irreversible stage of kidney impairment that cannot be controlled by conservative management alone and requires dialysis or kidney transplantation to maintain life. There are two levels of kidney impairment that can lead to ESRD: acute and chronic. End-stage renal disease (ESRD) implies chronic renal failure (CRF) of a degree (i.e., glomerular filtration rate, GFR<10–12 mL/min) such that life cannot be sustained long-term without dialysis. In contrast to acute kidney failure, chronic kidney failure is a permanent condition that leads to a progressive decline in renal function. Once it occurs, the kidneys cannot be made to function properly again, even when an inciting event has been corrected. CRF may exist for 10 to 20 years before progressing to ESRD. Over 70% of late-stage chronic kidney disease cases result from prolonged diabetes mellitus or hypertension. Glomerulonephritis, cystic diseases, and other urologic diseases account for another 12%, and 15% of patients have other or unknown causes of CRF. Long-term complications of chronic kidney disease (CKD) include a high risk of morbidity and mortality of cardiovascular disease compared to the general population. Mortality attributable to a cardiovascular cause accounts for 45% of all deaths of patients receiving dialysis. Between 80% and 90% of patients with CKD die of cardiovascular disease before reaching the need for dialysis. The precise biologic mechanisms for this are unclear. However, they may have to do with the uremic milieu, underlying coexistent comorbidities, and a hesitancy to perform investigative procedures in patients with chronic kidney disease.

End-stage renal disease (ESRD) incidence varies from 351 to 421 cases per million.

 

The competitive landscape of End-stage Renal Disease (ESRD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of End-stage Renal Disease (ESRD) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

End-stage Renal Disease (ESRD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: End-stage Renal Disease (ESRD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ISIS 416858      Ionis Pharmaceuticals, Inc.        Phase 2

2          Roxadustat       FibroGen          Phase 3

3          PINTA 745        Pinta Biotherapeutics     Phase 2

4          SNF472            Sanifit Therapeutics S. A.          Phase 2

5          Lanthanum carbonate    Shire    Phase 3

6          apabetalone      Resverlogix Corp           Phase 2

7          Sotatercept       Acceleron Pharma Inc.  Phase 2

8          SNF472            Sanifit Therapeutics S. A.          Phase 2

9          GB-0998           Japan Blood Products Organization        Phase 3

10        AB002  Aronora, Inc.     Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more